Skip to Content
Merck
CN

P5248

Etidronate disodium hydrate

≥97% (NMR), solid

Synonym(s):

Dihydrogen (1-hydroxyethylidene)bisphosphonate disodium hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C2H6Na2O7P2 · xH2O
CAS Number:
7414-83-7
Molecular Weight:
249.99 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
329820220
UNSPSC Code:
12352200
EC Number:
231-025-7
MDL number:
MFCD00152567

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Etidronate disodium hydrate, ≥97% (NMR), solid

InChI key

GWBBVOVXJZATQQ-UHFFFAOYSA-L

InChI

1S/C2H8O7P2.2Na/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);;/q;2*+1/p-2

SMILES string

[Na+].[Na+].CC(O)(P(O)([O-])=O)P(O)([O-])=O

assay

≥97% (NMR)

form

solid

color

white

mp

>300 °C

solubility

H2O: ≥10 mg/mL

storage temp.

2-8°C

Quality Level

100

Related Categories

Application

Etidronate disodium hydrate has been used in the synthesis of bisphosphonate derivatives of adenosine triphosphate (ATP)by T4 RNA ligase. It has also been sued to inhibit human farnesyl diphosphate synthase (FDPS).

Biochem/physiol Actions

Bisphosphonate antiresorptive agent. Less potent inhibitor of farnesyl diphosphate synthase (IC50 = 80 μM) as compared to the nitrogen containing bisphosphonates
Etidronate helps to guard chronic ocular hypertension prompted retinal oxidative stress. It stimulates the development of retinal ganglion cells through insulin-like growth factor 1 (IGF-1) signaling pathway. It may possess neuroprotective effects in in vivo and in vitro rat model of glaucoma. Etidronate belongs to bisphosphonates.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000521154
0000521153
0000521154
0000459594
0000459594

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Etidronate protects chronic ocular hypertension induced retinal oxidative stress and promotes retinal ganglion cells growth through IGF-1 signaling pathway
Su J and Huang M
European Journal of Pharmacology, 841, 75-81 (2018)
Synthesis of bisphosphonate derivatives of ATP by T4 RNA ligase
Sillero M A G, et al.
Febs Letters, 580(24), 5723-5727 (2006)
M R McClung et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 24(1), 301-310 (2012-10-20)
Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy
Nicole C Ferko et al.
Managed care (Langhorne, Pa.), 21(11), 44-52 (2012-12-15)
Because of rising drug expenditures, cost considerations have become essential, necessitating the requirement for cost-effectiveness analyses for managed care organizations (MCOs). The study objective is to examine the impact of various drug-cost components, in addition to wholesale acquisition cost (WAC)
Siyoung Kim et al.
European journal of pharmacology, 699(1-3), 14-22 (2012-12-04)
Nitrogen-containing bisphosphonates (NBPs) have greater anti-bone-resorptive effects than non-nitrogen-containing bisphosphonates (non-NBPs). Hence, NBPs are the current first-choice drug for osteoporosis. However, NBPs carry a risk of osteonecrosis of jaws. Some animal and human studies suggest that non-NBPs may have anti-bone-resorptive
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service